New Insider Zhai Yifan Joins Ascentage Pharma, Files Initial Ownership
| Field | Detail |
|---|---|
| Company | Zhai Yifan |
| Form Type | 3 |
| Filed Date | Mar 24, 2026 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: insider-ownership, form-3, new-insider, disclosure
TL;DR
**New insider Zhai Yifan just filed their initial ownership in Ascentage Pharma, watch for future trades.**
AI Summary
Zhai Yifan, a new insider at Ascentage Pharma Group International (CIK: 0002023311), filed a Form 3 on March 23, 2026, indicating their initial beneficial ownership of the company's securities as of March 18, 2026. This filing is a standard disclosure required when an individual becomes an officer, director, or beneficial owner of more than 10% of a company's stock. For investors, this matters because it signals a new key player has joined the company, and their future trading activity (reported on Forms 4 and 5) could provide insights into their confidence in Ascentage Pharma's prospects.
Why It Matters
This filing introduces a new insider, Zhai Yifan, to Ascentage Pharma, whose future stock transactions could signal confidence or concern about the company's performance.
Risk Assessment
Risk Level: low — A Form 3 is a routine disclosure of initial ownership and does not inherently indicate a positive or negative event for the company.
Analyst Insight
Smart investors should add Zhai Yifan to their insider tracking list for Ascentage Pharma and monitor future Form 4 filings for any buying or selling activity, which could provide signals about the company's outlook.
Key Players & Entities
- Zhai Yifan (person) — Reporting Person
- Ascentage Pharma Group International (company) — Issuer
- 0002123017 (person) — CIK for Zhai Yifan
- 0002023311 (company) — CIK for Ascentage Pharma Group International
FAQ
What is the purpose of the Form 3 filed by Zhai Yifan?
The Form 3 is an 'Initial statement of beneficial ownership of securities,' filed because Zhai Yifan became an insider (officer, director, or 10%+ owner) of Ascentage Pharma Group International, disclosing their initial holdings as of March 18, 2026.
When was the Form 3 filed and accepted by the SEC?
The Form 3 was filed on March 23, 2026, and accepted by the SEC on the same day, March 23, 2026, at 20:01:12.
Filing Stats: 764 words · 3 min read · ~3 pages · Grade level 9.2 · Accepted 2026-03-23 20:01:12
Filing Documents
- marketforms-72706.html (3)
- marketforms-72706.xml (3) — 11KB
- poa.htm (EX-24) — 6KB
- 0001213900-26-033149.txt ( ) — 18KB
From the Filing
SEC FORM 3 SEC Form 3 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5 1. Name and Address of Reporting Person * Zhai Yifan (Last) (First) (Middle) C/O ASCENTAGE PHARMA GROUP INC. 700 KING FARM BLVD., SUITE 510 (Street) ROCKVILLE MARYLAND 20850 (City) (State) (Zip) UNITED STATES (Country) 2. Date of Event Requiring Statement (Month/Day/Year) 03/18/2026 3. Issuer Name and Ticker or Trading Symbol ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ] 3a. Foreign Trading Symbol 5. If Amendment, Date of Original Filed (Month/Day/Year) 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Medical Officer 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Ordinary Shares 1,097,994 I See Footnote (2) (2) Ordinary Shares 22,054,131 I See Footnote (1) (1) Ordinary Shares 312,534 D Ordinary Shares 14,089,111 I See Footnote (5) (5) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5) Date Exercisable Expiration Date Title Amount or Number of Shares Options (3) 11/26/2035 Ordinary Shares 143,463 $ 8.14 (4) I See Footnote (2) (2) Options (3) 11/26/2035 Ordinary Shares 103,364 $ 8.14 (4) D Restricted share units (6) (6) Ordinary Shares 143,463 $ 0 I See Footnote (2) (2) Restricted share units (6) (6) Ordinary Shares 103,364 $ 0 D Explanation of Responses: 1. Shares held by Dajun Yang Dynasty Trust. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. 2. Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. 3. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. 4. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. 5. Securities held by ordinary shares held by HealthQuest Pharma Limited, an entity controlled by the Reporting Person. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. 6. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. Remarks: This form is filed using a special power of attorney. Thomas J. Knapp 03/20/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 3: SEC 1473 (03-26)